{
  "ticker": "LLY",
  "target_date": "2025-05-22",
  "actual_date": "2025-05-22",
  "collected_at": "2025-12-08T11:47:55.131646",
  "price": {
    "open": 714.48,
    "high": 719.55,
    "low": 708.95,
    "close": 712.5860595703125,
    "volume": 4249900,
    "change_1d_pct": -1.34,
    "change_7d_pct": -3.94,
    "change_30d_pct": -4.91
  },
  "technicals": {
    "rsi_14": 27.62,
    "sma_20": 779.57,
    "sma_50": 789.54,
    "macd": -22.227,
    "macd_signal": -17.432,
    "macd_histogram": -4.795,
    "bb_upper": 899.38,
    "bb_lower": 659.77,
    "price_vs_sma20_pct": -8.59,
    "price_vs_sma50_pct": -9.75,
    "volume_ratio": 0.83
  },
  "fundamentals": {
    "market_cap": 892534063104,
    "pe_ratio": 48.781197,
    "forward_pe": 43.93752,
    "price_to_book": 37.48585,
    "price_to_sales": 15.020819,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.46,
    "pct_from_52w_low": 59.61
  },
  "macro": {
    "spy": {
      "price": 579.76,
      "change_1d_pct": 0.04,
      "change_7d_pct": -0.77
    },
    "vix": {
      "level": 20.28,
      "signal": "ELEVATED"
    },
    "treasury_10y": {
      "yield_pct": 4.55
    },
    "dollar_index": {
      "level": 99.96
    },
    "gold": {
      "price": 3292.3
    },
    "regime": "BEAR_NORMAL"
  },
  "news": [
    {
      "headline": "Lilly announces details of presentations at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting",
      "source": "Yahoo",
      "datetime": 1747947900,
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced that data from studies of imlunestrant, an investigational oral selective estrogen receptor degrader (SERD), olomorasib, an investigational KRAS G12C inhibitor, LY4170156, an investigational antibody-drug conjugate (ADC) targeting folate receptor alp",
      "url": "https://finnhub.io/api/news?id=ce574d7401cb1d3ac9ccd8c58e39c632d42a4d1dca67349d2255f10d3821d432"
    },
    {
      "headline": "Top Analyst Reports for Eli Lilly, GE Aerospace & Amgen",
      "source": "Yahoo",
      "datetime": 1747946040,
      "summary": "Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), GE Aerospace (GE) and Amgen Inc. (AMGN).",
      "url": "https://finnhub.io/api/news?id=7175f9b5943a38d0306f0a5f41b12261a5475d803bf608fcadf6c19abc5e5651"
    },
    {
      "headline": "Cigna takes different approach with GLP-1s, more favorable for Eli Lilly",
      "source": "Yahoo",
      "datetime": 1747937399,
      "summary": "Investing.com -- Cigna\u2019s Evernorth has introduced a new pharmacy benefit that caps out-of-pocket costs for GLP-1 weight loss medications at $200 per month, in a move analysts say is more favorable for Eli Lilly (NYSE:LLY) than rival models.",
      "url": "https://finnhub.io/api/news?id=d67682388ad2176d0f449dcd0d68d9f092205709bca8f8e3f9904916ac8c844f"
    },
    {
      "headline": "Eli Lilly (NYSE:LLY) Wins Approval For Alzheimer's Drug Kisunla In Australia",
      "source": "Yahoo",
      "datetime": 1747935009,
      "summary": "Eli Lilly (NYSE:LLY) witnessed a modest 1.31% increase in its share price over the past week, coinciding with the Australian Therapeutic Goods Administration's approval of Kisunla, its novel Alzheimer's treatment, potentially adding positive investor sentiment. This development is significant given ",
      "url": "https://finnhub.io/api/news?id=96cb8513776d1ee748bb42d6ef65a90ab28d7c4826f5e662e51fb0a7d8465c2d"
    },
    {
      "headline": "GLP-1 diabetes drugs like Ozempic may modestly reduce cancer risks",
      "source": "Finnhub",
      "datetime": 1747934772,
      "summary": "Widely used GLP-1 drugs for type 2diabetes such as Novo Nordisk's Ozempic may modestlyreduce the risk of obesity-related cancers, especiallycolorectal cancer, according to data released on Thursday...",
      "url": "https://finnhub.io/api/news?id=ee48ec584bca285a9b9f5f7996e98c7672ba8b45a27b0f8b67c93fbcbbccbf3b"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-05-20",
      "description": "xslF345X05/wk-form4_1747772733.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000154/xslF345X05/wk-form4_1747772733.xml"
    },
    {
      "form": "4",
      "date": "2025-05-20",
      "description": "xslF345X05/wk-form4_1747772668.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000152/xslF345X05/wk-form4_1747772668.xml"
    },
    {
      "form": "4",
      "date": "2025-05-20",
      "description": "xslF345X05/wk-form4_1747772589.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000150/xslF345X05/wk-form4_1747772589.xml"
    },
    {
      "form": "4",
      "date": "2025-05-20",
      "description": "xslF345X05/wk-form4_1747772518.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000148/xslF345X05/wk-form4_1747772518.xml"
    },
    {
      "form": "4",
      "date": "2025-05-20",
      "description": "xslF345X05/wk-form4_1747772448.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000146/xslF345X05/wk-form4_1747772448.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}